Stereotactic radiosurgery in patients with extensive brain metastases – supporting evidence and knowledge gaps
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 21, 2023 Category: Cancer & Oncology Source Type: research

T2-FLAIR mismatch sign correlates with 11C-methionine uptake in lower-grade diffuse gliomas
ConclusionThe T2-FLAIR mismatch sign correlated with lower11C-methionine uptake in lower grade gliomas. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 17, 2023 Category: Cancer & Oncology Source Type: research

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series
ConclusionsThus, we underscored a role of SII as predictive value of response to STUPP protocol. Regarding the TME-related markers, we suggested to take into consideration for future studies with new immunotherapy combinations, each component relating to expression of immune infiltrating subsets. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 16, 2023 Category: Cancer & Oncology Source Type: research

Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis
ConclusionGlioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, are aggressive tumors with a very short long-term OS. SMR is an effective therapeutic approach contributing to increased PFS and OS in patients with this catastrophic disease. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 10, 2023 Category: Cancer & Oncology Source Type: research

Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 10, 2023 Category: Cancer & Oncology Source Type: research

Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis
ConclusionThe risk of g2  + IH exceeds that of g2 + RN in MBM patients undergoing SRS, with or without IO. IH should be considered a critical adverse event following MBM treatments.Graphical Abstract (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 8, 2023 Category: Cancer & Oncology Source Type: research

PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort
ConclusionsThePTPN11 variant was a negative prognostic indicator ofIDH-wildtype GBM in the patient cohort with the CGP assay. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 8, 2023 Category: Cancer & Oncology Source Type: research

First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial
ConclusionLMS continues to be a devastating progression in many types of cancer, including GBM, and novel ways to deliver therapeutics may offer patients symptomatic and therapeutic benefits. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 7, 2023 Category: Cancer & Oncology Source Type: research

Mapping high-grade glioma immune infiltration to 5-ALA fluorescence levels: TCGA data computation, classical histology, and digital image analysis
ConclusionWith mapping the immune infiltration pattern of different 5-ALA categories, we are adding fundamental basic insights to the field of 5-ALA and glioma biology. The observation that a significant correlation in TCGA data did not fully translate to detectable differences in immune infiltration in first histology data warrants further investigation in larger cohorts. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 6, 2023 Category: Cancer & Oncology Source Type: research

Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis
ConclusionWe conclude that less than 50% of patients with glioblastoma have a favorable short-term outcome when unplanned ICU treatment with IMV is required. Our data mandate a careful therapy guidance and frequent reassessment of goals during ICU stay. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - August 2, 2023 Category: Cancer & Oncology Source Type: research

Fractionated versus staged gamma knife radiosurgery for mid-to-large brain metastases: a propensity score-matched analysis
ConclusionsThis is the first study to compare f-GKRS and s-GKRS in large BMs. Fractionation is as effective as staged GKRS for treating mid-to-large BMs. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - July 31, 2023 Category: Cancer & Oncology Source Type: research

SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling
ConclusionSPOPL can be used as a potential prognostic biomarker for GBM in clinical work and promotes the proliferation and stemness of GSCs by activating the Notch signaling pathway, which may be a potential molecule for targeting GSCs to treat GBM. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - July 31, 2023 Category: Cancer & Oncology Source Type: research

Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme
ConclusionBZ-SRS with bevacizumab was feasible and well tolerated. There is no significant survival benefit using BZ-SRS with bevacizumab compared to institutional historical controls. Secondary analysis revealed a trend toward improved PFS-6, but not OS-6 after BZ-SRS. MRS scans did not result in changes to SRS treatment plans. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - July 29, 2023 Category: Cancer & Oncology Source Type: research

MR-guided LITT therapy in patients with primary irresectable glioblastoma: a prospective, controlled pilot study
ConclusionAn RCT to study the effectiveness of LITT in patients with an irresectable nGBM seems feasible with acceptable initial safety data. The findings from this pilot study helped to further refine the design of a larger full-scale multicenter RCT in the Netherlands.Protocol and study identifier:  The current study is registered at clinicaltrials.gov (EMITT pilot study, NTR: NCT04596930).Graphical abstract (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - July 28, 2023 Category: Cancer & Oncology Source Type: research

Correction to: Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR)
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - July 27, 2023 Category: Cancer & Oncology Source Type: research